

SUBSTANTIAL SHAREHOLDERS

So far as our Directors are aware, immediately following the completion of the [REDACTED] (assuming the [REDACTED] is not exercised and no further Shares are issued under the Pre-[REDACTED] Equity Incentive Plan), the following persons will have an interest or short position in the Shares or the underlying Shares which would fall to be disclosed to our Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO or, will be, directly or indirectly, interested in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of our Company or any other member of our Group:

Name of Shareholder	Capacity/ Nature of interest	As of the Latest Practicable Date ⁽¹⁾		Immediately following completion of the [REDACTED] ⁽²⁾	
		Number of Shares held	Approximate percentage of shareholding in the total issued share capital of our Company ^(%)	Number of Shares held	Approximate percentage of shareholding in the total issued share capital of our Company ^(%)
OrbiMed Advisors LLC	Interest in a controlled corporation ⁽⁴⁾⁽⁵⁾	37,516,778	32.6	[REDACTED]	[REDACTED]
OrbiMed Asia Partners III, L.P.	Beneficial interest	18,758,389	16.3	[REDACTED]	[REDACTED]
OrbiMed Asia GP III, L.P.	Interest in a controlled corporation ⁽³⁾	18,758,389	16.3	[REDACTED]	[REDACTED]
OrbiMed Advisors III Limited	Interest in a controlled corporation ⁽³⁾	18,758,389	16.3	[REDACTED]	[REDACTED]
OrbiMed Private Investments VII, LP	Beneficial interest	18,758,389	16.3	[REDACTED]	[REDACTED]
OrbiMed Capital GP VII LLC	Interest in a controlled corporation ⁽⁴⁾	18,758,389	16.3	[REDACTED]	[REDACTED]
Montar Capital, LLC	Beneficial interest	31,907,829	27.7	[REDACTED]	[REDACTED]
Creacion Ventures I, L.P.	Interest in a controlled corporation ⁽⁶⁾	31,907,829	27.7	[REDACTED]	[REDACTED]
Creacion Ventures GP I, LLC	Interest in a controlled corporation ⁽⁶⁾	31,907,829	27.7	[REDACTED]	[REDACTED]
Dr. Wei Li	Interest in a controlled corporation ⁽⁶⁾	31,907,829	27.7	[REDACTED]	[REDACTED]
Dr. Qingsheng Zhu.	Interest in a controlled corporation ⁽⁶⁾	31,907,829	27.7	[REDACTED]	[REDACTED]
Forward Force Investment Limited.	Beneficial interest	17,527,962	15.2	[REDACTED]	[REDACTED]
Boyu Capital Growth Fund I, Pte. Ltd.	Interest in a controlled corporation ⁽⁷⁾	17,527,962	15.2	[REDACTED]	[REDACTED]
Boyu Capital Growth Fund I, L.P.	Interest in a controlled corporation ⁽⁷⁾	17,527,962	15.2	[REDACTED]	[REDACTED]
Boyu Capital Growth GP I, Ltd..	Interest in a controlled corporation ⁽⁷⁾	17,527,962	15.2	[REDACTED]	[REDACTED]
Boyu Group, LLC	Interest in a controlled corporation ⁽⁷⁾	17,527,962	15.2	[REDACTED]	[REDACTED]
Mr. Xiaomeng Tong	Interest in a controlled corporation ⁽⁷⁾	17,527,962	15.2	[REDACTED]	[REDACTED]
HSG Growth VI Holdco E, Ltd..	Beneficial interest	12,269,573	10.7	[REDACTED]	[REDACTED]
HongShan Capital Growth Fund VI, L.P.	Interest in a controlled corporation ⁽⁸⁾	12,269,573	10.7	[REDACTED]	[REDACTED]
HSG Growth VI Management, L.P.	Interest in a controlled corporation ⁽⁸⁾	12,269,573	10.7	[REDACTED]	[REDACTED]
HSG Holding Limited	Interest in a controlled corporation ⁽⁸⁾	12,269,573	10.7	[REDACTED]	[REDACTED]
SNP China Enterprises Limited.	Interest in a controlled corporation ⁽⁸⁾	12,269,573	10.7	[REDACTED]	[REDACTED]
Mr. Neil Nanpeng Shen	Interest in a controlled corporation ⁽⁸⁾	12,269,573	10.7	[REDACTED]	[REDACTED]

SUBSTANTIAL SHAREHOLDERS

Notes:

- (1) The number of Shares held assuming that all of the preferred Shares have been converted into the Shares on a one-to-one basis.
- (2) The calculation is based on the total number of [REDACTED] Shares in issue immediately following completion of the [REDACTED] (assuming the [REDACTED] is not exercised and no further Shares are issued under the Pre-[REDACTED] Equity Incentive Plan).
- (3) As of the Latest Practicable Date, the general partner of OrbiMed Asia Partners III, L.P. (“**OrbiMed Asia**”) is OrbiMed Asia GP III, L.P., with OrbiMed Advisors III Limited acting as its general partner. Accordingly, OrbiMed Asia GP III, L.P. and OrbiMed Advisors III Limited are deemed to be interested in the Shares held by OrbiMed Asia under the SFO.
- (4) As of the Latest Practicable Date, the general partner of OrbiMed Private Investments VII, LP (“**OrbiMed U.S.**”) is OrbiMed Capital GP VII LLC, with OrbiMed Advisors LLC being its managing member. Accordingly, OrbiMed Capital GP VII LLC and OrbiMed Advisors LLC are deemed to be interested in the Shares held by OrbiMed U.S. under the SFO.
- (5) OrbiMed Advisors LLC is the advisory company to OrbiMed Asia, pursuant to its voting power under the advisory agreement between it and OrbiMed Asia. OrbiMed Advisors LLC also has controlling voting power over OrbiMed U.S. Therefore, OrbiMed Asia and OrbiMed U.S. are under common control of OrbiMed Advisors LLC and OrbiMed Advisors LLC is deemed to be interested in the Shares held by OrbiMed Asia and OrbiMed U.S. under the SFO.
- (6) As of the Latest Practicable Date, Creacion Ventures GP I, LLC is the manager of Montar Capital, LLC (“**Creacion**”). Creacion Ventures I, L.P. holds 90.8% limited partnership interest in Montar Capital, LLC. Creacion Ventures GP I, LLC is held as to 50% by Dr. Wei Li and 50% by Dr. Qingsheng Zhu. Accordingly, Dr. Wei Li, Dr. Qingsheng Zhu, Creacion Ventures GP I, LLC and Creacion Ventures I, L.P. are deemed to be interested in the Shares held by Montar Capital, LLC under the SFO.
- (7) As of the Latest Practicable Date, Forward Force Investment Limited is wholly owned by Boyu Capital Growth Fund I, Pte. Ltd., which is in turn wholly owned by Boyu Capital Growth Fund I, L.P.; the sole general partner of Boyu Capital Growth Fund I, L.P. is Boyu Capital Growth GP I, Ltd., which is in turn wholly owned by Boyu Group, LLC, which is in turn ultimately controlled by Mr. Xiaomeng Tong. Accordingly, Boyu Capital Growth Fund I, Pte. Ltd., Boyu Capital Growth Fund I, L.P., Boyu Capital Growth GP I, Ltd., Boyu Group, LLC and Mr. Xiaomeng Tong are deemed to be interested in the Shares held by Forward Force Investment Limited under the SFO.
- (8) As of the Latest Practicable Date, HSG Growth VI Holdco E, Ltd. is wholly owned by HongShan Capital Growth Fund VI, L.P., the general partner of which is HSG Growth VI Management, L.P., whose general partner is in turn HSG Holding Limited, a wholly-owned subsidiary of SNP China Enterprises Limited. Mr. Neil Nanpeng Shen is the sole shareholder of SNP China Enterprises Limited. Accordingly, HongShan Capital Growth Fund VI, L.P., HSG Growth VI Management, L.P., HSG Holding Limited, SNP China Enterprises Limited and Mr. Neil Nanpeng Shen are deemed to be interested in the Shares held by HSG Growth VI Holdco E, Ltd. under the SFO.

Save as disclosed herein, our Directors are not aware of any persons who will, immediately following completion of the [REDACTED] (assuming the [REDACTED] is not exercised and no further Shares are issued under the Pre-[REDACTED] Equity Incentive Plan), without taking into account the [REDACTED] that may be taken up under the [REDACTED], have any interests or short positions in the Shares or underlying Shares which would fall to be disclosed to our Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO or, will be, directly or indirectly, interested in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of our Company or any other member of our Group.